Blood-Based Multiomics-Guided Detection of a Precancerous Pancreatic Tumor

OMICS. 2024 Apr;28(4):182-192. doi: 10.1089/omi.2023.0278. Epub 2024 Apr 17.


Over a decade ago, longitudinal multiomics analysis was pioneered for early disease detection and individually tailored precision health interventions. However, high sample processing costs, expansive multiomics measurements along with complex data analysis have made this approach to precision/personalized medicine impractical. Here we describe in a case report, a more practical approach that uses fewer measurements, annual sampling, and faster decision making. We also show how this approach offers promise to detect an exceedingly rare and potentially fatal condition before it fully manifests. Specifically, we describe in the present case report how longitudinal multiomics monitoring (LMOM) helped detect a precancerous pancreatic tumor and led to a successful surgical intervention. The patient, enrolled in an annual blood-based LMOM since 2018, had dramatic changes in the June 2021 and 2022 annual metabolomics and proteomics results that prompted further clinical diagnostic testing for pancreatic cancer. Using abdominal magnetic resonance imaging, a 2.6 cm lesion in the tail of the patient's pancreas was detected. The tumor fluid from an aspiration biopsy had 10,000 times that of normal carcinoembryonic antigen levels. After the tumor was surgically resected, histopathological findings confirmed it was a precancerous pancreatic tumor. Postoperative omics testing indicated that most metabolite and protein levels returned to patient's 2018 levels. This case report illustrates the potentials of blood LMOM for precision/personalized medicine, and new ways of thinking medical innovation for a potentially life-saving early diagnosis of pancreatic cancer. Blood LMOM warrants future programmatic translational research with the goals of precision medicine, and individually tailored cancer diagnoses and treatments.

Keywords: diagnosis; longitudinal monitoring; multiomics; pancreatic cancer; personalized medicine; precision oncology.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers, Tumor / blood
  • Early Detection of Cancer / methods
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Metabolomics / methods
  • Middle Aged
  • Multiomics
  • Pancreatic Neoplasms* / blood
  • Pancreatic Neoplasms* / diagnosis
  • Pancreatic Neoplasms* / genetics
  • Pancreatic Neoplasms* / surgery
  • Precancerous Conditions* / blood
  • Precancerous Conditions* / diagnosis
  • Precancerous Conditions* / pathology
  • Precision Medicine / methods
  • Proteomics / methods


  • Biomarkers, Tumor